TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of patients with pVL <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: rate of recurrent UTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: rate of subsequent pyelonephritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: development of renal parenchymal scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Daily defaecation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percent reduction in mSWAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric upset
Endpoint domain: Adverse events/effects
Primary endpoint: composite end point of cardiovascular death, HF hospitalization, and aborted sudden death
Endpoint domain: Mortality/survival
Primary endpoint: Antidepressant use among participants
Endpoint domain: Adverse events/effects
Primary endpoint: Habitual soft drink consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for FF nasal spray over FP nasal spray
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient compliance with FF treatment versus FP treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adverse events reported during treatment with FF
Endpoint domain: Adverse events/effects
Primary endpoint: 30-day recurrent bleeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ulceration greater than 2 x 1 cm
Endpoint domain: Adverse events/effects
Primary endpoint: clinically relevant coagulation abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: mean reduction in daily rTNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean reduction in morning rTNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean reduction in evening rTNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Q‐TWiST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AKI incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time till recovery of AKI episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: MVC torque decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Peak serum CK activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: worse outcome at 30 day or 2.7 year follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Healthy babies born
Endpoint domain: Mortality/survival
Primary endpoint: Pregnancies reaching >10 weeks gestation
Endpoint domain: Mortality/survival
Primary endpoint: Levels of MDA and GSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: delayed complications
Endpoint domain: Adverse events/effects
Primary endpoint: Agreement between observers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in PHQ-8
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in RD
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Polymorphonuclear neutrophils in bronchoalveolar lavage fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood tissue plasminogen activator levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard deviation of normal-to-normal intervals (SDNN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resolution of echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of ICU days
Endpoint domain: Resource use
Endpoint subdomain: ICU
Primary endpoint: Decrease in bullying and cyberbullying behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in capacity for empathy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diagnostic uncertainty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytogenetic damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft tissue discoloration compared to natural gingiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stenosis decrease to an average of 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patency of the reconstructed artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to full activity within 1 week
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: success in carrying out everyday activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Accuracy of FDG PET data analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single trial bolus before shock resolved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of fluid delivered (ml/kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Haemoglobin difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Risk of ACL injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Total pain level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic pain level in sitting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy intake after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in LVEF at peak stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in BNP values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in GT PGF2alpha levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of good result (GR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of moderate disability (MD)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of hematoma absorbability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PACU length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Response rates for awareness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Identification of first signs of stroke
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak Expiratory Flow (PEF) measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: relief of somatic-type symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevention of oedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerance of compression stockings
Endpoint domain: Adverse events/effects
Primary endpoint: Corticosteroid-sparing at week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality improvement of family physicians' practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lump detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Examination technique use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual reinfection rate of H. pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: risk of myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: composite risk of myocardial infarction, stroke, lower-extremity amputation, and mortality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arrest of leathery non-cavitated primary root caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum cephalic spread time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose of propofol required for hypnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pain-free period after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue analgesic requirement during 24-hour postoperative period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HADS-T scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Protein S100 release
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum potassium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Electrolyte outcomes
Primary endpoint: Withdrawal due to hyperkalemia
Endpoint domain: Adverse events/effects
Primary endpoint: seminal quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Definitive hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Vaccine response against pertussis component
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dental injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FFIS score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Elevated lung water (EVLWI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung suitability for transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recipient survival
Endpoint domain: Mortality/survival
Primary endpoint: sensitivity of DSE for detection of significant CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: specificity of DSE for detection of significant CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: prevalence of significant CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pHi levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum amyloid A values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test-retest reliability of PA Home Environment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hands-off time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilator tidal volume (VT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak inspiratory pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: etravirine exposure decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: headache incidence
Endpoint domain: Adverse events/effects
Primary endpoint: grade 3 triglyceride increase
Endpoint domain: Adverse events/effects
Primary endpoint: Complete bile duct stone removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post‐procedure complications
Endpoint domain: Adverse events/effects
Primary endpoint: Cholangitis occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: BIS and AAI values at LORverbal and LORlash
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction probability for OAA/S scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of LORnoxious
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-intubation peak mean arterial pressure (MAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak tachycardiac response to intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean peri-implant marginal bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiation dose equivalent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnostic accuracy for hepatic metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year colostomy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: tumor diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent dose adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serious adverse events following BAL
Endpoint domain: Adverse events/effects
Primary endpoint: Time to placement of arterial lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of attempts to place arterial lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of arterial line placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of HER2-positive CTCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Lives saved by screening mammography
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients not developing moderate visual loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in logMAR BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of lines lost
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Average daily urinary phosphorus excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average daily fecal phosphorus excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effectiveness of FC activity
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Willingness to participate in the trial again
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stroke Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physical exercise duration
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Surface area covered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final temperatures at the end of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with anesthetic and warming technique
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: vascular death/myocardial infarction within 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of ventricular tachyarrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Length of stay after cardiac surgery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: specificity of intraoperative detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity of intraoperative detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AKSS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: VAS score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: proportion of participants with virologic success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean CD4 increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Weight loss at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of ascites, pleural effusions and/or leg oedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of dental fluorosis (TF > 0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of TF scores 2 or 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of demarcated opacities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Basal plasma levels of ACTH and cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: disability score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leg pain score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum COR concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive and emotional support perception
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Abstinence at 6-month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of hemorrhage with first tourniquet placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to hemorrhage control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Simulated blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Noninferiority of hydromorphone for street heroin use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Noninferiority for any street opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious adverse events related to injection medication
Endpoint domain: Adverse events/effects
Primary endpoint: serum non-transferrin-bound iron concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain scores using the visual analogue scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement of PIP joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity in detecting inflammatory changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity in detecting inflammatory changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TAG-72 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: catD concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PR expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accuracy rate of IA elbow injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in practice patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean paired differences for the M component (spherical equivalent)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Small significant differences in the astigmatic components (J0 and J45)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of voids per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urge incontinence episodes per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean voided volume per void
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma level of SOD1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of pleural effusion
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary recovery of biotin and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bioavailability of oral biotin doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: comprehensive pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hand use
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of cTBS-induced decrement in inhibition restored
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: overall quality scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: quality of disease activity assessment and treatment decisions
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: time-to-discharge readiness
Endpoint domain: Resource use
Endpoint subdomain: Hospital